<DOC>
	<DOC>NCT01299571</DOC>
	<brief_summary>An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of AVODART administered in Korean BPH patients according to the prescribing information</brief_summary>
	<brief_title>AVODART(Dutasteride) Post-marketing Surveillance(PMS)</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>The Korean BPH Patients administrated dutasteride according to the prescribing information women and children and adolescents. patients with hypersensitivity to dutasteride, other 5alpha reductase inhibitors, or any of the excipients.</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>